Publications by authors named "P Caffarra"
Article Synopsis
- The Itel-MMSE is an easy-to-use telephone screening tool for dementia that gained traction during COVID-19 but needed validation and faced issues like a ceiling effect.
- This study standardized and validated the Itel-MMSE, recruiting 707 healthy participants and 368 individuals with Mild Cognitive Impairment and Alzheimer's Disease to establish new cut-off scores.
- Results indicated that the Itel-MMSE is effective in identifying dementia, with strong performance metrics in distinguishing between normal conditions and cognitive impairments, supporting its use in remote screenings.
Introduction: Approximately 2 million people in Italy are currently living with dementia or mild cognitive impairment (MCI), and 4 million are involved as family members or caregivers. Considering the significant impact of dementia, the Italian Ministry of Health entrusted the Italian National Institute of Health (Istituto Superiore di Sanità) with the development of a guideline within the Italian National Guideline System (Sistema Nazionale Linee Guida, SNLG) on the diagnosis and treatment of dementia and MCI. The main objective was to provide evidence-based recommendations aimed at reducing the variability and ensuring the appropriateness of clinical practices throughout the whole care process from identification and diagnosis to the end of life for people with dementia (PwD) or MCI and their families/caregivers.
View Article and Find Full Text PDFCognition-oriented treatments (COTs) are a group of non-pharmacological treatments aimed at maintaining or improving cognitive functioning. Specific recommendations on the use of these interventions in people living with dementia (PLwD) are included in the Italian Guideline on the Diagnosis and Treatment of Dementia and Mild Cognitive Impairment, developed by the Italian National Institute of Health. This systematic review and meta-analysis, based on the GRADE methodology, is part of the guideline.
View Article and Find Full Text PDFPurpose: According to preclinical evidence, GLP-1 receptor may be an actionable target in neurodegenerative disorders, including Alzheimer's disease (AD). Previous clinical trials of GLP-1 receptor agonists were conducted in patients with early AD, yielding mixed results. The aim was to assess in a proof-of-concept study whether slow-release exenatide, a long-acting GLP-1 agonist, can benefit the cognitive performance of people with mild cognitive impairment (MCI).
View Article and Find Full Text PDF